Reference for detection of tumor-related mutation genes in circulating free DNA
By optimizing the reference product combination and preparation process, a reference product disk covering 33 hot-spot tumor-related gene mutation sites was developed, solving the problems of high detection cost and low efficiency in the prior art, and achieving high efficiency and low cost Multi-gene multi-mutation site detection.
Patent Information
- Application Number
- CN202210293003.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-03-23
AI Technical Summary
Existing tumor-related reference products cannot meet the detection needs of multiple genes and multiple mutation sites at the same time, and the number of uses is large, covering fewer genotypes and mutation sites, resulting in high detection costs and low detection efficiency.
An optimized human tumor mutation detection reference plate was developed. Through the optimization of reference product combination and preparation process, it contains 9 positive reference products that can be used independently, each reference product covers 33 hot tumor-related gene mutation sites. Use a small number to achieve detection of more genes and mutation sites, and has excellent quality control performance.
It significantly reduces detection costs and R&D costs, improves detection efficiency, can meet the detection needs of multiple genes and multiple mutations on the market, has excellent quality control performance, and is suitable for free DNA detection in plasma.
Smart Images

Figure GDA0005084827850000071 
Figure GDA0005084827850000081 
Figure GDA0005084827850000171
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene detection, and in particular to a reference product used in detection. The present invention provides a reference product for detecting tumor-related mutation genes in plasma free DNA, in particular as a positive mutation reference product for circulating free DNA (cfDNA). A reference product plate containing the reference product, a kit, and a method for preparing the reference product are also provided. Background Art
[0002] Currently, the main source of information about tumor genes is still the tumor tissue samples of the subjects. However, for some patients with advanced cancer, tumor tissue samples are not available and are not suitable for dynamic monitoring.
[0003] A large number of clinical studies have shown that there is circulating free DNA (cfDNA) in peripheral blood, and that cfDNA in the peripheral blood of cancer patients contains circulating tumor DNA (ctDNA). Detection of free DNA such as cfDNA or ctDNA in plasma (or serum) can avoid invasive tissue biopsy and facilitate repeated sample collection.
[0004] Using cfDNA or ctDNA in plasma samples, we can obtain information about mutations in tumor-related genes. This information helps predict the progression of cancer patients, helps select targeted drugs, and helps predict treatment prognosis. Therefore, ctDNA gene testing in plasma samples of some cancers has been recommended by clinical consensus.
[0005] Since the content of tumor ctDNA in the sample is relatively low, the in vitro detection of tumor ctDNA requires very high detection technology. In recent years, only methods such as droplet digital PCR (ddPCR) and high-throughput sequencing (NGS) have been widely used to detect ctDNA mutations.
[0006] Reference products are an important part of the in vitro diagnostic process based on genetic testing. Reference products play an important role in the entire process of research and development of therapeutic drugs and diagnostic reagents. In the process of drug and reagent research and development, appropriate reference products are needed in the quality inspection of raw materials, semi-finished products and finished products, and the confirmation of reagent performance.
[0007] In the detection of ctDNA mutations, the requirements for reference material types, stability, detection limits and other parameters are more stringent. The rationality of reference material settings and the performance of reference materials play a key role in reagent quality control.
[0008] In addition, there are many links in the entire test kit product development process that require the use of reference materials, so reference materials also closely affect the R&D costs.
[0009] At the same time, by designing the configuration of reference materials to reduce the number of test reactions, the cost of clinical testing can be greatly reduced, thereby alleviating the medical burden on patients and society.
[0010] At present, many companies have launched tumor mutation cfDNA detection kits. In these kits, most of the DNA that constitutes the reference product is obtained by mechanical shearing or enzyme cutting. By combining these DNAs according to the distribution of the target mutation and mixing them with wild-type DNA, a reference product is finally formed. In such a reference product, the target mutation is included at a certain mutation frequency. For example, CN110578002A (Guangzhou Burning Stone Medical Laboratory Co., Ltd.) discloses a variety of quality control products for detecting circulating tumor DNA mutations.
[0011] However, the reference materials used in the kits of various companies on the market cannot meet the above requirements at the same time. These reference materials are used in large quantities and cover fewer gene types and mutation sites.
[0012] Therefore, it is expected to achieve simultaneous coverage of more genes and / or multiple mutation sites with a smaller number of references. Summary of the invention
[0013] The inventors have innovatively developed an optimized reference sample plate for detecting human tumor mutations. By optimizing the reference sample combination method and preparation process, the performance is improved and the cost is significantly reduced.
[0014] The reference product plate of the present invention is suitable for samples of free DNA (including cfDNA and ctDNA) in plasma. The reference product plate of the present invention contains positive reference products, specifically 9 positive reference products that can be used independently, each of which contains a group of mutations. The 9 positive reference products cover a total of 33 hot tumor-related gene mutation sites, which can meet the detection needs of multiple genes and multiple mutations on the market, and have excellent quality control performance.
[0015] In a first aspect, the present invention provides a reference material for detecting mutations in plasma free DNA, wherein the reference material comprises a wild-type DNA fragment and one or more mutant DNA fragments, each of the mutant DNA fragments has one or more base mutations and the encoded amino acid sequence has the amino acid mutations listed in Table 1.
[0016] Preferably, the amino acid sequence encoded by the mutant DNA fragment in the reference product comprises a combination of multiple amino acid mutations selected from any one of groups (a) to (i), and does not contain any amino acid mutations from other groups.
[0017] (a) EGFR amino acid mutation p.E746_A750del,
[0018] EGFR amino acid mutation p.T790M,
[0019] EGFR amino acid mutation p.L858R,
[0020] KRAS amino acid mutation p.G12C;
[0021] (b) EGFR amino acid mutation p.G719A,
[0022] EGFR amino acid mutation p.E746_A750del,
[0023] The amino acid mutation p.Q61K of NRAS,
[0024] KRAS amino acid mutation p.G12V;
[0025] (c) EGFR amino acid mutation p.G719S,
[0026] ALK amino acid mutation EML4-ALK,
[0027] BRAF amino acid mutation p.V600E,
[0028] KRAS amino acid mutation p.G12D,
[0029] amino acid mutation p.H1047R in PIK3CA;
[0030] (d) EGFR amino acid mutation p.L747_P753 indel S,
[0031] EGFR amino acid mutation p.S768I,
[0032] KRAS amino acid mutation p.G13C,
[0033] The amino acid mutation of ERBB2 is p.A775_G776insYVMA;
[0034] (e) EGFR amino acid mutation p.C797S,
[0035] KRAS amino acid mutation p.G13D,
[0036] The amino acid mutation p.E545K in PIK3CA;
[0037] (f) KRAS amino acid mutation p.G12S,
[0038] EGFR amino acid mutation p.L747_A750delinsP,
[0039] The amino acid mutation p.E542K in PIK3CA;
[0040] (g) ALK amino acid mutation EML4-ALK,
[0041] KRAS amino acid mutation p.G12A;
[0042] (h) KRAS amino acid mutation p.Q61H,
[0043] EGFR amino acid mutation p.L861Q,
[0044] Amino acid mutation of MET 14 exon skipping;
[0045] (i) EGFR amino acid mutation p.E746_S752delinsV,
[0046] EGFR amino acid mutation D770_N771insG,
[0047] RET amino acid mutation KIF5B-RET,
[0048] Amino acid mutations of ROS1 CD74-ROS1,
[0049] EGFR amino acid mutation p.G719C.
[0050] In one embodiment, the mutant DNA fragments and wild-type DNA fragments have a molecular weight distribution similar to that of natural cfDNA. In another embodiment, the average length of the mutant DNA fragments and wild-type DNA fragments is a fragment of 130-170 bp.
[0051] In one embodiment, the ratio of the mutant DNA fragment to the wild-type DNA fragment in the reference is such that the frequency of each base mutation in the reference is 0.1-10%, preferably 1-5%, and more preferably about 3%.
[0052] In a preferred embodiment, the base mutation contained in the reference is the base mutation listed in Table 1 corresponding to the amino acid mutation.
[0053] In a specific embodiment, the reference comprises a base mutation selected from any one of the following groups (a)-(i),
[0054] In (a), the base mutation of p.E746_A750del is c.2235_2249del15,
[0055] The base mutation of p.T790M is c.2369C>T,
[0056] The base mutation of p.L858R is c.2573T>G,
[0057] The base mutation of p.G12C is c.34G>T;
[0058] In (b), the base mutation of p.G719A is c.2156G>C,
[0059] The base mutation of p.E746_A750del is c.2236_2250del15,
[0060] The base mutation of p.Q61K is c.181C>A,
[0061] The base mutation of p.G12V is c.35G>T;
[0062] In said I, the base mutation of said p.G719S is c.2155G>A,
[0063] The subtypes of EML4-ALK are E6; A20,
[0064] The base mutation of p.V600E is c.1799T>A,
[0065] The base mutation of p.G12D is c.35G>A,
[0066] The base mutation of p.H1047R is c.3140A>G;
[0067] In (d), the base mutation of p.L747_P753 indel S is c.2240_2257del18,
[0068] The base mutation of p.S768I is c.2303G>T,
[0069] The base mutation of p.G13C is c.37G>T,
[0070] The base mutation of p.A775_G776insYVMA is c.2324_2325ins12;
[0071] In (e), the base mutation of p.C797S is c.2389T>A,
[0072] The base mutation of p.G13D is c.38G>A,
[0073] The base mutation of p.E545K is c.1633G>A;
[0074] In (f), the base mutation of p.G12S is c.34G>A,
[0075] The base mutation of p.L747_A750delinsP is c.2239_2248delinsC,
[0076] The base mutation of p.E542K is c.1624G>A;
[0077] In (g), the subtype of EML4-ALK is E13; A20,
[0078] The base mutation of p.G12A is c.35G>C;
[0079] In (h), the base mutation of p.Q61H is c.183A>T,
[0080] The base mutation of p.L861Q is c.2582T>A,
[0081] The base mutation of 14 exon skipping is c.3082+1G>T;
[0082] In (i), the base mutation of p.E746_S752delinsV is c.2237_2255delinsT,
[0083] The base mutation of D770_N771insG is c.2310_2311insGGT,
[0084] The subtypes of KIF5B-RET are K15; R12,
[0085] The subtypes of CD74-ROS1 are C6; R34,
[0086] The base mutation of p.G719C is c.2155G>T.
[0087] In a specific embodiment, the wild-type DNA fragment and the mutant DNA fragment are obtained by breaking a nucleotide molecule known to contain the base mutation, such as the genomic DNA of a cell line known to contain the base mutation, into fragments of appropriate length. Preferably, the breaking is performed by enzyme digestion or ultrasonic treatment.
[0088] In a specific embodiment, for a reference product comprising a mutation in any one of the groups (a) to (h), the DNA fragments are obtained by enzymatic digestion of genomic DNA of a cell line known to contain the base mutation. In a preferred embodiment, the enzymatic digestion is performed using an Atlantis enzyme to obtain DNA fragments similar to cfDNA in natural plasma.
[0089] In a specific embodiment, for a reference sample comprising a mutation in group (i), the DNA fragments are obtained by ultrasonically fragmenting DNA from a sample derived from a clinical sample or the like.
[0090] In a specific embodiment, the mixing of the wild-type DNA fragment and the mutant DNA fragment can be performed in a human plasma matrix.
[0091] The second aspect is a reference plate, which comprises the reference described in the first aspect as a positive reference. In a preferred embodiment, the reference plate comprises or only comprises 9 positive references, wherein the 9 positive references respectively comprise a group of mutations in (a) to (i) and do not contain any mutations in other groups.
[0092] The third aspect is a kit, which comprises the reference sample disc of the second aspect. The kit preferably further comprises one or more of a negative reference sample, a detection limit reference sample and a repeatability reference sample, preferably all of them.
[0093] In a specific embodiment, the detection limit reference has the same mutation combination and different mutation frequencies as a positive reference, preferably having a mutation combination of group (c). In a specific embodiment, the frequency of mutations other than fusion mutations in the detection limit reference is 0.3%, and the mutation frequency of fusion mutations is 0.4%. In a preferred embodiment, the kit comprises a plurality of, preferably 9, detection limit references. The 9 detection limit references correspond to the 9 positive references, respectively.
[0094] In a specific embodiment, the kit contains 9 positive reference substances prepared in the examples of the present invention, 9 detection limit reference substances, 2 negative reference substances, and 2 repeatability reference substances.
[0095] In a specific embodiment, the two repetitive references are a positive repetitive reference R1 having the same mutation combination as one of the positive references, and a negative repetitive reference R2 having no mutation. In a specific embodiment, the mutation frequency in the repetitive reference is 1%.
[0096] In a specific embodiment, the kit has the composition shown in Table 7.
[0097] The fourth aspect is the use of the reference product of the first aspect, the reference product disc of the second aspect or the kit of the third aspect in detecting ctDNA mutations. Preferably, the detection is performed by a method selected from the following: droplet digital PCR (ddPCR), amplification retardation mutation system PCR (ARMS) and high-throughput sequencing (NGS).
[0098] The fifth aspect is a DNA library prepared by the above-mentioned reference material. The DNA library is prepared by common operations in the art. In a specific embodiment, the library is used for sequencing and the like.
[0099] The sixth aspect is a method for preparing the reference sample plate comprising 9 positive reference samples according to the second aspect, comprising:
[0100] (1) For each mutation, providing genomic DNA containing a wild-type gene and genomic DNA containing a mutant gene;
[0101] (2) breaking the genomic DNA of step (1) into fragments of similar size to naturally occurring cfDNA to obtain wild-type DNA fragments (simulated WT-cfDNA) and mutant DNA fragments (simulated cfDNA) corresponding to each mutation;
[0102] (3) According to the grouping shown in Table 1, the mutant DNA fragments (simulated cfDNA) obtained in step (2) are mixed with the wild-type DNA fragments (simulated WT-cfDNA) according to the frequency of the base mutation to obtain a reference plate containing 9 positive references.
[0103] Preferably, the fragmentation is performed by enzymatic digestion or ultrasonic treatment.
[0104] In a specific embodiment, for a reference product comprising a mutation in any one of the groups (a) to (h), the DNA fragments are obtained by enzymatic digestion of genomic DNA of a cell line known to contain the base mutation. In a preferred embodiment, the enzymatic digestion is performed using an Atlantis enzyme to obtain DNA fragments similar to cfDNA in natural plasma.
[0105] In a specific embodiment, for a reference sample comprising a mutation in group (i), the DNA fragments are obtained by ultrasonically fragmenting DNA from a sample derived from a clinical sample or the like.
[0106] In a specific embodiment, the mixing of the wild-type DNA fragment and the mutant DNA fragment can be performed in a human plasma matrix.
[0107] Table 1 Mutation types contained in the reference product (HGVS format)
[0108]
[0109]
[0110] Preferably, the predetermined base mutation frequency is 0.1% to 10%, preferably 0.3% to 3%.
[0111] Preferably, the genomic DNA in step (1) is derived from a cell line.
[0112] For example, the genomic DNA is cellular nucleosomal DNA.
[0113] Preferably, the step (2) breaks the genomic DNA into fragments of 130-170 bp.
[0114] In a seventh aspect, the present invention provides a reference plate prepared by the method of the sixth aspect.
[0115] In an eighth aspect, the present invention relates to a kit comprising the reference sample disc of the seventh aspect.
[0116] In the ninth aspect, the present invention relates to a method for detecting gene mutations in circulating tumor DNA (ctDNA) or circulating free DNA (cfDNA), comprising using the reference substance of the first aspect, the reference substance disc of the second aspect or the seventh aspect, or the kit of the third aspect or the eighth aspect.
[0117] In a specific embodiment, the detection of the ninth aspect can be performed by a method selected from the group consisting of droplet digital PCR (ddPCR), amplification retardation mutation system PCR (ARMS) and high-throughput sequencing (NGS).
[0118] The advantages of the present invention are at least embodied in the following aspects.
[0119] 1. Compared with existing reference products, the reference disc and kit of the present invention can greatly reduce the number of reactions required through appropriate mutation combinations, under the premise that the monitored gene type is equivalent to the mutation type, thereby reducing the cost of using the reference product. In particular, when the reference product is used as an internal reference product of an enterprise, the development and quality control costs of products (drugs, reagents) can be greatly reduced;
[0120] 2. The detection of cfDNA or ctDNA samples has strict requirements on the detection limit. The reference sample plate and the kit of the present invention have good performance and low detection limit, and are suitable for detection with strict requirements on the detection limit.
[0121] 3. The positive reference product, the reference product plate and the kit of the present invention cover four concentration gradients of high, medium, low and negative, which can meet the needs of various detection methods. In the present invention, the sample source of the positive reference product does not include plasmid sources, which complies with the regulations of the State Food and Drug Administration and is guaranteed in terms of safety. DETAILED DESCRIPTION OF THE INVENTION
[0123] The terms used in this application are defined below. Terms not defined herein should be interpreted based on the common understanding of those skilled in the relevant art.
[0124] definition
[0125] "cfDNA" is the abbreviation of circulating free DNA, which refers to DNA fragments released into the blood, usually 50-200bp in length.
[0126] "Simulated cfDNA" or "simulated...cfDNA" refers to artificially prepared DNA fragments that are comparable to cfDNA in molecular weight size and / or length. Specifically, it refers to DNA fragments with a molecular weight distribution and / or length distribution similar to natural cfDNA. Molecular weight distribution means that in a collection of DNA fragments, the percentages of DNA fragments of various molecular weights in the collection are roughly the same. Similarly, length distribution means that in a collection of DNA fragments, the percentages of DNA fragments of various nucleotide lengths in the collection are roughly the same.
[0127] "ctDNA" is the abbreviation for circulating tumor DNA, which refers to DNA fragments derived from tumors and released into the blood (in the case of detection, such as in plasma samples).
[0128] "Genomic DNA" herein refers to chromosomal DNA, which is different from extrachromosomal DNA such as free DNA. This term emphasizes the existence and source of DNA, but does not limit the DNA referred to to necessarily include a complete genome. For example, genomic DNA can be a part of a complete genome.
[0129] "Droplet digital PCR" or "ddPCR" is a digital PCR performed using water-in-oil emulsion droplets. Unlike conventional PCR, the amplification reaction of ddPCR does not occur in Eppendorf tubes or microplate wells, but in droplets. In ddPCR, the sample is divided into nanoliter droplets, and the reaction in each droplet occurs independently and can also be measured independently.
[0130] "Reference materials" specifically refer to reference samples used in the testing of human genetic testing-related reagents, which have one or more determined properties and can be used for quality control, such as controlling the positive compliance rate of the reagents.
[0131] A "reference panel" is the combination of all reference materials used in an assay.
[0132] A "positive reference" refers to a reference that is known to contain a certain target mutation to be detected (sometimes also called a mutation-positive reference).
[0133] "Negative" refers to a reference that is known to not contain a certain target mutation to be detected, such as a reference that does not contain a gene mutation associated with a disease. An example of a negative reference is a reference derived from a wild-type (WT) or healthy sample.
[0134] A "negative reference" refers to a reference that does not contain the mutation to be tested, also known as a negative reference for the test gene locus, and sometimes also referred to as a wild-type and other homologous gene locus positive reference.
[0135] "Repeatability reference" can also be called precision reference, which is used to reflect the repeatability of product testing and the stability of repeated testing. The repeatability reference of the present invention can contain one or more common mutation types.
[0136] “Detection limit reference material”, “detection limit reference material” and “minimum detection limit reference material” are used without distinction.
[0137] "Mutation frequency" refers to the proportion of mutant DNA in a population of DNA fragments. In a specific embodiment, a sample with a predetermined mutation frequency is obtained by mixing wild-type DNA with mutant DNA, wherein the mutation frequency is the weight percentage of mutant DNA in the total DNA in the sample.
[0138] In a preferred embodiment, this reference plate covers a variety of mutation frequencies. Since the mutation frequency is the weight percentage of mutant DNA in the total DNA, different mutation frequencies can be regarded as the concentration gradient of the mutation. For point mutations and insertions and deletions, this reference plate covers a gradient of 3% (high concentration), 1% (medium concentration), and 0.3% (low concentration), which is consistent with the setting requirements of national detection reference products. For fusion genes, it is 3% (high concentration), 1% (medium concentration), and 0.4% (low concentration). 0% is the negative concentration.
[0139] "Tumor" refers to an abnormal tissue that has an independent and unrestricted growth tendency arising from the original body cells. In this article, "tumor" is used without distinction with "cancer" or "tumor".
[0140] "Wild type" (WT) refers to a gene, strain or characteristic that is commonly found in individuals in a natural population. In this context, wild type can also be interpreted as the absence of a mutation for the purpose of detection.
[0141] "Mutant" means that a mutation has occurred compared to the wild type. Mutant can also be understood as having a mutation associated with a disease to be detected.
[0142] "Wild-type DNA fragment" refers to a fragmented DNA having a base arrangement consistent with the wild type, which is understood to be not a complete DNA chain. As a source of wild-type cell lines, commercially available BEAS-2B, GM12878 and GM24385 cell lines can be used.
[0143] "Mutant DNA fragment" refers to a fragment of DNA having a mutated base sequence compared to the wild type, which can be understood as not a complete DNA chain, and in this context, specifically refers to a DNA fragment having a mutation to be detected.
[0144] "Tumor-associated mutant gene" refers to a gene whose mutation is associated with the development, progression, and prognosis of a tumor.
[0145] "High-throughput sequencing" is also known as next-generation sequencing (NGS).
[0146] “Mutational mutual exclusion” means that mutation sites from the same exon are assigned to different references, or that different base mutations occurring in the same mutation site come from different cell lines and are assigned to different references.
[0147] Matrix
[0148] In the reference product, the nucleic acid molecule needs to be dissolved in a matrix for use. As the matrix, a negative (WT) matrix that is the same as or has similar properties to the clinical sample can be used, such as a healthy human plasma matrix. In subsequent embodiments of the present invention, when the mutant DNA fragments are mixed with the wild-type DNA fragments, no matrix may be used.
[0149] Mutation type
[0150] The descriptions of the mutation types described in the present invention are all named according to the rules of the Human Genome Variation Society (HGVS).
[0151] For example, the prefix "p." indicates a human protein reference sequence; the prefix "c." indicates a human cDNA reference sequence.
[0152] Substitution (>): A nucleotide is replaced by another nucleotide, indicated by the use of ">".
[0153] Deletion (del): One or more nucleotides are removed, described using "del".
[0154] Inversion (inv): A new nucleotide sequence (greater than 1 nucleotide) that is the reverse complement of the original sequence replaces the original sequence.
[0155] Duplication (dup): One or more nucleotide copies are inserted directly downstream of the original sequence, indicated by "dup".
[0156] Insertion (ins): One or more nucleotides are inserted into a sequence, and the inserted sequence is not a copy of the upstream sequence.
[0157] Deletion-insertion (delins / indel): One or more nucleotides are replaced by other nucleotides, but substitution, inversion and transposition do not occur.
[0158] Conversion (con): A special type of deletion-insertion in which the nucleotide sequence replacing the original sequence is a copy of a sequence from another site in the genome.
[0159] For example, in this article, p.E746_A750del means that compared with the human protein reference sequence, E at position 746 to A at position 750 is deleted; p.T790M means that compared with the human protein reference sequence, T at position 790 is changed to M, that is, T represents (Threonine) threonine, M represents (Methionine) methionine, and T790M refers to the conversion of C to T at the 790th code of the EGFR gene, resulting in the conversion of the amino acid at this site from threonine to methionine; p.A775_G776insYVMA means that compared with the human protein reference sequence, the amino acid sequence YVMA is inserted between A at position 775 and G at position 776; p.L747_A750delinsP means that compared with the human protein reference sequence, the sequence between L at position 747 and A at position 750 is replaced by amino acid P, and it is not substitution, inversion or conversion. "c." indicates that the sequence is compared with the human cDNA reference sequence. For example, +1 in c.3082+1G>T represents the first base of the intron next to this exon. For example, EML4-ALK refers to the fusion gene of EML4 and ALK, and 14exonskipping refers to the skipping deletion of exon 14 at the mRNA level. Those skilled in the art can accurately determine the meaning of these codes.
[0160] Regarding the description of mutations in fusion genes, such as the EML4-ALK fusion gene, the known general classification is to divide patients into four groups: E13; A20, E20; A20, E6; A20 and other subtypes. Those skilled in the art can determine the mutation information represented by subtypes such as E13; A20, etc.
[0161] The reaction number corresponding to the reference product plate of the present invention can be calculated by the following formula:
[0162] Number of reactions = positive reference + negative reference + repeatability reference * 10 + detection limit reference
[0163] Reference tray
[0164] One embodiment of the present invention is a reference sample plate for detecting tumor-related gene mutations. The reference sample plate comprises a positive reference, and the positive reference is at least one, two, three, four, five, six, seven, eight or nine selected from the positive references 1-9 shown in Table 1, preferably nine.
[0165] The reference sample plate may further include at least 1, 2, 3, 4, 5, 6, 7, 8 or 9 of the 9 detection limit reference samples S1-S9 shown in Table 1, preferably 9.
[0166] The reference plate may further comprise a repeat reference and a negative reference.
[0167] The repeatability references may include at least one positive repeatability reference and at least one negative repeatability reference.
[0168] The positive repeatability reference is preferably obtained by diluting the positive reference in Table 1, more preferably by diluting the positive reference p3, and the dilution multiple is preferably 3. After dilution, the mutation frequency in the repeatability reference is 1%. The negative repeatability reference is prepared by the same preparation method as the positive reference of the present invention, from a normal wild-type cell line WT.
[0169] Each of the above reference products in the reference product tray can be used independently or in any combination according to actual needs.
[0170] For example, at least one, two, three, four, five, six, seven, eight or nine selected from the positive references 1 to 9 may be used as positive references. At least one, two, three, four, five, six, seven, eight or nine selected from the detection limit references S1 to S9 may be used. At least one or two of the repeatability references may be used. At least one or two of the negative references may be used.
[0171] In one embodiment, the reference sample plate comprises 22 reference samples, including positive reference samples 1 to 9, detection limit reference samples S1-S9, 2 negative reference samples and 2 repeatability reference samples.
[0172] Reagent test kit
[0173] One embodiment is a kit comprising 1, 2, 3, 4, 5, 6, 7, 8 or 9 of the positive reference substances P1-9 shown in Table 1.
[0174] Preferably, the kit further comprises a negative reference, a detection limit reference, and a repeatability reference.
[0175] The kit may further include other commonly used sequencing reagents such as sequencing reaction solution, sequencing primers, etc.
[0176] Preparation method
[0177] One embodiment of the present invention is a method for preparing a reference substance for detecting tumor mutations, wherein the reference substance comprises:
[0178] (1) Using enzymatic digestion to digest genomic DNA, wild-type cfDNA1 and mutant cfDNA1 were obtained from normal cell lines and tumor cell lines;
[0179] (2) using ultrasound to disrupt the genomic DNA (gDNA) of the cell line to obtain wild-type cfDNA2 and mutant cfDNA2;
[0180] (3) Mixing mutant cfDNA1 with wild-type cfDNA1 in a certain combination and ratio to obtain a corresponding reference product;
[0181] (4) The mutant cfDNA in (2) is mixed with the wild-type cfDNA in a certain ratio to obtain the corresponding reference material.
[0182] In a specific embodiment, the enzyme is Atlantis double-stranded DNA enzyme, which cleaves genomic DNA. The inventors have confirmed in previous experiments that the nucleic acid distribution of simulated cfDNA obtained using this enzyme is very similar to the nucleic acid distribution of natural cfDNA.
[0183] It should be noted that the source of these mutant DNA fragments containing mutations, such as specific cell lines, is not subject to any limitation, as long as such DNA fragments can be obtained.
[0184] For example, mutant DNA fragments containing mutations can be obtained from cells known to contain these mutations by the above-mentioned enzyme digestion method, etc. In addition, mutant DNA fragments can come from clinical samples, immortalized cell lines, gene-edited cell lines, genetic engineering products, and recombinant plasmids, etc. In other words, mutant DNA fragments can be obtained from commercially available plasmids, or obtained from cell lines known to contain these mutations by PCR technology, genetic engineering, etc., or obtained by artificial synthesis based on sequence information, etc.
[0185] When the reference product of the present invention is used as a part of a test kit for a human subject, preferably, the source of the mutant DNA fragment does not include a plasmid.
[0186] Among them, the cell line that can be used as the source of the mutant DNA fragment of the present invention is preferably a tumor cell line. Specifically, the cell line used as the source of the mutant DNA fragment of the present invention can be exemplified by the cell lines shown in Table 2.
[0187] use
[0188] One embodiment of the present invention is the use of the above-mentioned reference material in a method for detecting ctDNA mutations, such as use in droplet digital PCR (ddPCR), amplification retardation mutation system PCR (ARMS) and high-throughput sequencing (NGS) methods.
[0189] The reference sample plate or kit of the present invention can be used to detect the cfDNA form of tumor-related mutant genes. As the disease / tumor type corresponding to the gene mutation that can be detected by the present invention, for example, non-small cell lung cancer, colorectal cancer, melanoma, breast cancer, endometrial cancer, ovarian cancer, lung cancer, etc.
[0190] The reference product disc or kit of the present invention can be used for clinical purposes. As a specific example, the use of ctDNA mutation frequency can be used to predict the medication (such as gefitinib, icotinib hydrochloride, osimertinib mesylate, crizotinib) and the efficacy of cancer patients, and can also be used for early screening of cancer, detecting the sensitivity of immune checkpoint inhibitor therapy, predicting the risk of recurrence and / or survival of patients, etc.
[0191] The reference sample plate or kit of the present invention can also be used in the development or performance verification of reagents, quality control, comparison of the consistency of platform results under different methods, etc. Specific examples include:
[0192] 1) As a reference product for enterprises, the raw materials, semi-finished products and finished products of products (test kits for plasma DNA detection, including but not limited to NGS method, PCR method, etc.) can be tested;
[0193] 2) When used in clinical testing, it can be used as a yardstick for internal employee training and assessment; it can be used as a negative or positive control to monitor the experimental process and prove whether the experimental process is effective. Example
[0194] The scheme of the present invention will be explained below in conjunction with embodiments. It will be understood by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.
[0195] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0196] Example 1. Preparation and detection of reference products
[0197] In this example, positive reference substances and negative reference substances, repeatability reference substances and detection limit reference substances containing tumor-related mutations of the present invention were prepared.
[0198] In order to achieve the purpose of the present invention, the inventors optimized the design of the reference materials to obtain the grouping in Table 1 so that the detection kit can simultaneously cover multiple genes and multiple mutation sites with a small number of reference materials.
[0199] In the grouping, try to make different mutations of the same gene not be in the same reference. However, if the same gene contains more than 9 mutations, different mutations from the same exon of the gene are not placed in the same reference. Try to make a specific mutation in a reference come from only one cell line, and try to make the mutations contained in different cell lines mutually exclusive (the same cell line does not contain different base mutations occurring in the same mutation site at the same time).
[0200] For example, 8 KRAS mutations, 3 RIK3CA mutations, and 2 ALK mutations were placed in different references respectively; for the 14 EGFR mutations, they involved exons 18 (3 mutations), 19 (5 mutations), 20 (3 mutations), and 21 (2 mutations) of the EGFR gene respectively. Mutation sites from the same exon (for example, all KRAS sites are in exon 2, and the same base will become 3 types) were assigned to different references, which is beneficial to reduce the probability of false positives or false negatives in PCR.
[0201] It should be noted that, for the cell line used as the source, a commercially available cell line can be used. Generally, one cell line contains one mutation, and some cells contain two mutations. As long as the cell line has the corresponding mutation, it is not limited to the cell lines exemplified in Table 2.
[0202] Finally, the inventors obtained 9 positive references shown in Table 1, which contained a total of 33 mutation sites, and can be used as 9 enterprise plates. The specific preparation method and effect test process are described below.
[0203] 1.1 Raw material selection
[0204] 1.1.1 Cells and culture media
[0205] The sources of samples used in the preparation of the reference plate are shown in Table 2 below.
[0206] Table 2. Correspondence between mutations and source cell lines
[0207]
[0208] Among them, there were 5 mutation sites that had no corresponding cell lines, so clinical samples or standards were used, as shown in Table 3 below:
[0209] Table 3 Other mutation sites
[0210]
[0211] Note: The standard products mentioned above are standard products and reference materials approved by the China Food and Drug Inspection Institute (CFDA).
[0212] 1.1.2 Enzymes
[0213] Atlantis double-stranded DNA enzyme, i.e., Atlantis dsDNase (available from, for example, ZOMO research, 2030, 12.5u, or sold as part of the EZ Nucleosomal DNA Prep Kit (D5220)).
[0214] 1.2 Preparation process
[0215] 1.2.1 Preparation and detection of positive reference substances P1-P8
[0216] Simulated cfDNA was prepared using Atlantis double-stranded DNA enzyme digestion. Specifically, the cell lines shown in Table 2 were used to prepare mutant DNA fragments (simulating tumor cfDNA), and human healthy negative cell lines were used to prepare wild-type DNA fragments (simulating WT-cfDNA).
[0217] The specific preparation steps are as follows:
[0218] (1) Culture cells using the corresponding culture medium as described in 1.1.1. Take about 1×10 6 cells;
[0219] (2) Wash the cells with phosphate buffer, collect the cells after centrifugation at 200 × g, and repeat the washing once;
[0220] (3) Discard the supernatant, resuspend the cells in 1 ml of phosphate buffer, and transfer to a 1.5 ml centrifuge tube;
[0221] (4) Centrifuge and discard the supernatant, add 100 μL of nucleic acid preparation solution (the main component is 0.25% trypsin, and the pH is adjusted to 8.0 with NaHCO3), resuspend the cell pellet by blowing with a pipette or inverting the test tube, and incubate on ice for 5 minutes;
[0222] (5) Collect the cellular nucleic acid by centrifugation and discard the supernatant;
[0223] (6) Wash the cells with 100 μL of Atlantis digestion solution (main components: 20 mg / mL proteinase K, 50 mM Tris-HCl1, pH 8.0), mix by inverting 2-3 times, and centrifuge to discard the supernatant;
[0224] (7) Repeat step (6) once;
[0225] (8) Gently resuspend the cell nucleic acid in 100 μL of Atlantis digestion solution;
[0226] (9) Add 10 μL of Atlantis double-stranded DNA enzyme and gently tap the tube to mix;
[0227] (10) Digestion and incubation at 42°C for 40 min;
[0228] (11) Add 20 μL of reaction stop solution (main component: 0.5 M EDTANa2, pH adjusted to 8.0 with NaOH), vortex to mix, and terminate the reaction;
[0229] (12) Add 600 μL of DNA binding solution (main components: 5 M hydrochloride, 20% propylene glycol, 0.12 M acetate) and vortex to mix;
[0230] (13) Transfer to a centrifuge column (already installed in a collection tube), centrifuge at 10,000-13,000 × g for 30 seconds, and discard the filtrate;
[0231] (14) Add 300 μL of DNA cleaning solution (mainly 80% ethanol), centrifuge at 10,000-13,000 × g for 30 seconds, and discard the filtrate;
[0232] (15) Repeat step (14) once;
[0233] (16) Centrifuge the empty tube for 1 minute to remove the remaining washing solution and transfer the centrifuge column to a new 1.5 ml centrifuge tube;
[0234] (17) Add 30 μL of DNA elution buffer (mainly composed of 0.01 M Tris-HCl, 0.01 M EDTA) to the centrifuge column and let stand at room temperature for 3 min;
[0235] (18) Centrifuge for 30 seconds to collect the purified DNA, i.e., the enzyme-digested cfDNA.
[0236] The wild-type DNA fragment WT-cfDNA was used as a negative sample, and the mutant DNA fragment was used as a positive sample, and mixed according to the amount of DNA in the combination shown in Table 1, so that the expected mutation frequency of each mutation in the respective reference was 3%. No reagent other than the sample was added during the mixing process.
[0237] The mutations covered by the positive references P1 to P8 are shown in Table 4 , respectively.
[0238] 1.2.2 Preparation and detection of positive reference substance P9
[0239] For the reference product P9, simulated cfDNA was prepared using ultrasonic shearing. Specifically, mutant DNA fragments were prepared using the sample sources shown in Table 3, and wild-type DNA fragments WT-cfDNA were prepared using human negative clinical samples.
[0240] The steps for treating cells using ultrasound are as follows.
[0241] 1. Turn on the Covaris M220 instrument switch and the "SonoLab" software on the computer desktop, add ultrapure water to the water tank, the water level should be flush with or slightly higher than the required position of the sample tube holder, and you can interrupt when "Run" is green;
[0242] 2. Prepare a PCR tube and a DNA shearing tube for each FFPE sample and label them separately.
[0243] 3. Take 55 ng of FFPE sample DNA into a PCR tube and add nuclease-free water to 55 μL;
[0244] Note: If the total DNA of the FFPE sample is less than 55 ng, use the maximum volume of sample DNA to build the library.
[0245] 4. Vortex the DNA dilution solution to mix well, centrifuge briefly, transfer all the liquid to the corresponding DNA fragmentation tube, centrifuge briefly, and place the fragmentation tube into the fragmentation instrument.
[0246] 5. Interruption parameters: Duty Factor 25%; Average Incident Power 18.8; Peak IncidentPower (PIP) 75; Cycles per Burst 1000; Water Temperature 9°C (max), 5°C (min); Treatment Time 300s;
[0247] 6. After the shearing is completed, remove the DNA shearing tube, transfer all the liquid to a new labeled PCR tube after a brief centrifugation, take another 30 μL of the sheared DNA for library construction, and store the remaining DNA at -20°C.
[0248] Wild-type DNA (WT-DNA) was used as a negative sample without mutation, and other ultrasonically sheared DNAs were used as positive samples with mutations, which were mixed and prepared so that the expected mutation frequency of each mutation in the respective reference was 3% (mass fraction, the same below), and they were mixed according to the composition of P9 in Table 1 to obtain the positive reference P9.
[0249] Table 4. Mutation information of positive reference samples
[0250]
[0251]
[0252] 1.2.3 Preparation of negative reference
[0253] Using the same method as in 1.2.1, negative reference N1 was prepared using the NCI-H1395 cell line, and negative reference N2 was prepared using the healthy human cell line GM24631. Negative reference N1 does not contain the mutations described in Table 1, and negative reference N2 does not contain any known pathogenic positive mutations.
[0254] 1.2.4 Preparation of detection limit reference materials
[0255] Detection limit references S1-S8 were prepared using the same method and sources as in 1.2.1.
[0256] S1-S8 have the same mutation composition as P1-P8 respectively, but are different from P1-P8 in the mixing ratio of wild-type DNA fragments and mutant DNA fragments.
[0257] Specifically, the detection limit references S1-S8 were obtained by mixing wild-type DNA fragments and mutant DNA fragments according to the expected mutation frequency of 0.3% corresponding to each mutation (wherein the mutation frequency of fusion mutation was 0.4%).
[0258] The detection limit reference S9 was prepared using the same method and sources as in 1.2.2. S9 has the same mutation composition as P9, but differs in the mixing ratio of wild-type DNA fragments and mutant DNA fragments.
[0259] The wild-type DNA fragment and the mutant DNA fragment were mixed according to the expected mutation frequency of 0.3% corresponding to each mutation (wherein the mutation frequency of the fusion mutation was 0.4%) to obtain the detection limit reference material S9.
[0260] 1.2.5 Preparation of repeatability reference materials
[0261] The repeatability positive reference R1 and repeatability negative reference R2 were prepared using the same method as in 1.2.1.
[0262] R1 has the same mutation composition as the positive reference P3, but differs from P3 in the mixing ratio of wild-type DNA fragments and mutant DNA fragments. The wild-type DNA fragments and mutant DNA fragments were mixed according to the expected mutation frequency of each mutation, 1%, to obtain the detection limit reference R1.
[0263] R2 was obtained by dilution of simulated WT-cfDNA.
[0264] 1.3 Quality Inspection
[0265] 1.3.1 Positive reference quality inspection
[0266] The internal quality inspection and third-party quality inspection using the droplet digital PCR method detected the detection values of each mutation frequency in the positive reference products P1 to P9, and are shown in Table 5 below.
[0267] Table 5 ddPCR quality inspection results of reference products
[0268]
[0269]
[0270] The results showed that among the 33 mutation sites contained in the positive reference products P1 to P9, the internal detection results were consistent with the ddPCR detection results, which proved that the positive reference products of the present invention had good consistency with the gold standard recognized in the industry and met the requirements.
[0271] 1.3.2 Quality inspection of detection limit reference materials
[0272] The prepared detection limit reference products S1 to S9 were sent to a third-party testing company for ddPCR testing. After comparison and summary, the NGS test results of the 33 mutation sites contained in the reference products were consistent with the ddPCR detection results, as shown in Table 6. This result shows that the detection limit reference products can be detected and function normally.
[0273] Table 6 Internal and ddPCR detection of detection limit reference materials
[0274]
[0275]
[0276] 1.3.3 NGS testing
[0277] Considering that the application scenario of the reference product is plasma samples, the matrix of plasma samples was studied. Among them, the DNA of negative cell WT was replaced with normal human negative plasma DNA, and the positive DNA sample was added to the normal human negative plasma matrix in a certain proportion and DNA was extracted using nucleic acid extraction or purification reagents. The extracted DNA was library built and sequenced on the machine. The final NGS test results were consistent with expectations, as shown in Table 8.
[0278] 1.4 Combination of reference trays
[0279] The positive reference of the present invention is preferably used in combination with the above-mentioned negative reference, detection limit reference, and repeatability reference as a reference plate.
[0280] Example 2. Comparison with other reference plates
[0281] In this example, the composition of the reference product of the present invention and some commercially available reference products / kits were statistically analyzed and compared, and the results are shown in Table 7. The reaction numbers in Table 7 were calculated according to the following formula.
[0282] Number of reactions = positive reference + negative reference + repeatability reference * 10 + detection limit reference
[0283] In Table 7, A = Guangzhou Burning Rock Medical Laboratory Co., Ltd., "EGFRALKBRAFKRAS Gene Mutation Combined Detection Kit (Reversible Terminal Termination Sequencing Method)"; B = Nanjing Shihe Gene Biotechnology Co., Ltd., "EGFRALKROS1BRAFKRASHER2 Gene Mutation Detection Kit (Reversible Terminal Termination Sequencing Method)"; C = Tianjin Novogene Bioinformatics Technology Co., Ltd., "Human EGFR-KRAS-BRAF-PIK3CA-ALK-ROS1 Gene Mutation Detection Kit (Semiconductor Sequencing Method)"; D = Xiamen Aide Biotechnology Co., Ltd., "Human 10 Gene Mutation Combined Detection Kit (Reversible Terminal Termination Sequencing Method)".
[0284] Table 7. Comparison with other commercial kits
[0285]
[0286]
[0287] From the results, it can be seen that compared with reference product A, the reference product plate of the present invention has the same number of mutant gene types and mutation site types, but the total number of reference products is reduced by 56.86%, and the number of reference product reactions is reduced by 78.49%; compared with reference product B, the mutant gene types and mutation site types of the reference product plate of the present invention increased by about 1.5 times and 1.54 times, respectively, the total number of reference products was reduced by 47.62%, and the number of reference product reactions was reduced by 54.02%; compared with reference product C, the mutant gene types and mutation site types of the reference product plate of the present invention increased by about 0.67 times and 0.65 times, respectively, the total number of reference products was reduced by 4.35%, and the number of reference product reactions was reduced by 32.2%; compared with reference product D, although the mutation site types of the reference product plate of the present invention were reduced by about 0.15 times, the mutant gene types increased by 0.67 times, the total number of reference products was reduced by 77.32%, and the number of reference product reactions was reduced by 75%.
[0288] In summary, compared with reference products of other companies on the market, the reference product disc of the present invention has more mutant gene types and mutation types, which can meet the detection needs of multiple genes and multiple mutations on the market. At the same time, the total number of reference products contained in the reference product disc of the present invention is only 22, and the total number of reference product reactions is only 40, which significantly reduces the R&D cost and detection cost of the relevant detection kit containing the reference product.
[0289] Example 3. Operation repeatability verification
[0290] In this example, in order to explore the effects of different batches of cell sources used to prepare reference materials and different experimenters on the detection of reference material mutations, operation repeatability verification was performed.
[0291] First, operator 1 prepared 9 reference discs P1 to 9 with a mutation frequency of 3% according to the same preparation process as in Example 1. These samples were tested by NGS to determine the mutation frequency in the references, and the results were verified by ddPCR, and the NGS results were in line with expectations.
[0292] Afterwards, operator 2 extracted nucleosomal DNA from different batches of cells, and used the extracted DNA to repeat the preparation of reference products P1 to 9 according to the same preparation method as above, and also performed verification.
[0293] The NGS test results obtained by the standards prepared by operators 1 and 2 were compared and the results are shown in Table 8.
[0294] Table 8.3% Next-generation sequencing (NGS) test results of reference disk
[0295]
[0296]
[0297] The results show that, as can be seen from Table 5, the reference plate prepared by the preparation method of the present invention can still obtain similar results even if different batches of cells are used and operated by different personnel, and the difference from the expected mutation frequency is within an acceptable range.
[0298] Industrial Applicability
[0299] The reference plate of the present invention can be used in the detection application of tumor-related gene mutations in cfDNA. The reference plate of the present invention can be used not only for clinical detection, but also for reagent development, such as for verifying reagent performance, performing quality control, and comparing the consistency of results of different methods and platforms.
Claims
1. A reference product for preparing a kit for detecting circulating tumor DNA mutations, It is characterized in that The reference materials include: The wild-type DNA fragment, and A plurality of mutant DNA fragments, each of which has a plurality of base mutations and the encoded amino acid sequence has a plurality of amino acid mutations listed in Table 1; The amino acid sequence encoded by the mutant DNA fragment in the reference product comprises the following amino acid mutations (a) to (i), and does not contain any amino acid mutations in other groups: (a) EGFR amino acid mutation p. E746_A750del, EGFR amino acid mutation p. T790M, EGFR amino acid mutation p. L858R, KRAS amino acid mutation p. G12C; (b) EGFR amino acid mutation p. G719A, EGFR amino acid mutation p. E746_A750del, NRAS amino acid mutation p. Q61K, KRAS amino acid mutation p. G12V; (c) EGFR amino acid mutation p. G719S, ALK amino acid mutation EML4-ALK, BRAF amino acid mutation p. V600E, KRAS amino acid mutation p. G12D, amino acid mutation p.H1047R in PIK3CA; (d) EGFR amino acid mutation p. L747_P753 indel S, EGFR amino acid mutation p. S768I, KRAS amino acid mutation p. G13C, ERBB2 amino acid mutation p. A775_G776insYVMA; (e) EGFR amino acid mutation p. C797S, KRAS amino acid mutation p. G13D, PIK3CA amino acid mutation p. E545K; (f) KRAS amino acid mutation p. G12S, EGFR amino acid mutation p.L747_A750delinsP, PIK3CA amino acid mutation p. E542K; (g) ALK amino acid mutation EML4-ALK, KRAS amino acid mutation p. G12A; (h) KRAS amino acid mutation p. Q61H, EGFR amino acid mutation p. L861Q, Amino acid mutation of MET 14 exon skipping; (i) EGFR amino acid mutation p.E746_S752delinsV, EGFR amino acid mutation D770_N771insG, RET amino acid mutation KIF5B-RET, Amino acid mutations of ROS1 CD74-ROS1, EGFR amino acid mutation p. G719C; The mutant DNA fragment in the reference contains the following base mutations (a) to (i), and does not contain any base mutations in other groups: (a) corresponding to the base mutation c.2235_2249del15 of p.E746_A750del, The base mutation c.2369C>T corresponding to the p.T790M, The base mutation c.2573T>G corresponding to p.L858R, The base mutation c.34G>T corresponding to the p.G12C; (b) corresponding to the base mutation c.2156G>C of p.G719A, The base mutation c.2236_2250del15 corresponding to the p.E746_A750del, The base mutation c.181C>A corresponding to p. Q61K, The base mutation c.35G>T corresponding to the p. G12V; (c) corresponding to the base mutation c.2155G>A of p.G719S, Corresponding to the subtype E6 of EML4-ALK; A20, The base mutation c.1799T>A corresponding to p. V600E, Corresponding to the base mutation c.35G>A of p.G12D, The base mutation c.3140A>G corresponding to the p.H1047R; (d) corresponding to the base mutation c.2240_2257del18 of p.L747_P753 indel S, The base mutation c.2303G>T corresponding to p. S768I, The base mutation c.37G>T corresponding to p.G13C, The base mutation c.2324_2325ins12 corresponding to the p.A775_G776insYVMA; (e) corresponding to the base mutation c.2389T>A of p.C797S, Corresponding to the base mutation c.38G>A of p.G13D, The base mutation c.1633G>A corresponding to the p.E545K; (f) corresponding to the base mutation c.34G>A of p.G12S, The base mutation c.2239_2248delinsC corresponding to the p.L747_A750delinsP, The base mutation c.1624G>A corresponding to the p.E542K; (g) corresponds to the subtypes E13 and A20 of EML4-ALK. The base mutation corresponding to p. G12A is c.35G>C; (h) corresponding to the base mutation c.183A>T of p.Q61H, The base mutation c.2582T>A corresponding to p.L861Q, The base mutation c.3082+1G>T corresponding to the 14 exon skipping; (i) the base mutation c.2237_2255delinsT corresponding to the p.E746_S752delinsV, The base mutation c.2310_2311insGGT corresponding to the D770_N771insG, Corresponding to the subtypes K15 and R12 of KIF5B-RET, Corresponding to the subtype C6 of CD74-ROS1; R34, The base mutation c.2155G>T corresponding to the p.G719C.
